UTMD offers defensive value through 60% gross margins, net cash equal to 37.6% of market cap, and litigation-driven upside if revenue stabilizes and direct biopharma sales gain traction.
Overview
Utah Medical Products is a niche medical device manufacturer with a highly defensive financial profile built around proprietary, disposable products for women’s health, neonatal care, and critical care. **The core debate is simple: UTMD has elite margins and a fortress balance sheet, but weak top-line momentum.** FY2025 revenue fell to $38.52 million, down 5.8% year over year and 23.3% from FY2023, reflecting OEM attrition and weaker international demand. Even so, the company remains highly profitable, and in Q1 2026 gross margin improved to **60.6%** from 57.0% despite a 10.2% sales decline. UTMD also carries $87.406 million of cash and investments against just $210 thousand of debt, giving the stock strong downside support.
The company’s competitive position comes from clinically entrenched consumables like the Filshie Clip, INTRAN PLUS, DISPOSA-HOOD, and Deltran transducers, supported by switching costs, regulatory barriers, and owned manufacturing sites in Utah, Ireland, and the UK. Near-term catalysts include progress in replacing lost OEM revenue through direct biopharma sensor sales, resolution of remaining Filshie Clip litigation, and more assertive capital returns via buybacks or special dividends. **Valuation is supported by an 8.84x EV/EBITDA multiple and cash equal to 37.6% of market capitalization**, but the investment case still depends on stabilizing revenue.